Development of peptide vaccination targeting novel musculoskeletal sarcoma antigens

我们对患有播散性滑膜肉瘤或骨肉瘤的患者进行了I期临床肽疫苗接种试验。对于滑膜肉瘤，完成了试验，证实了SYT-SSX肽疫苗接种的安全性和有效性。对于骨肉瘤，实验仍在继续，我们从骨恶性纤维组织细胞瘤和上皮肉瘤中鉴定出癌干细胞样细胞。此外，我们建立了识别HLA I类肿瘤干细胞样细胞的自体细胞毒性T淋巴细胞克隆。这些观察结果为靶向癌症干细胞样细胞的免疫治疗打开了大门。

We performed phase I clinical peptide vaccination trials for patients with disseminated synovial sarcoma or osteosarcoma. For synovial sarcoma, the trial was completed and the safety and efficacy of SYT-SSX peptide vaccination was confirmed. For osteosarcoma, the trial is continued.We identified cancer-stem like cells from malignant fibrous histiocytoma of the bone and epithelial sarcoma. Furthermore, we established autologous cytotoxic T-lymphocyte clone recognizing cancer-stem like cells in the context of HLA class I. These observations open the door toward immunotherapy targeting cancer-stem like cells.